| Website | esperion.com |
| Category | BioTech |
| Phone | 734-332-0506 |
| Employees | |
| Founded | 1998 |
| Description | Treatment of cardiovascular |
| Series A, 5/08 Alta Partners Domain Associates Arboretum Ventures Aisling Capital | $22.8M |
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called “HDL Therapy,” which is based on the Company’s understanding of high-density lipoprotein, or HDL, function.
